Jyothy Laboratories Ltd is adding more stockists, strengthening their direct delivery through the retailer’s app and enhancing focus on e-commerce platforms.

Chirag Batavia • 10 August 2020

Jyothy Laboratories Ltd

 JYL’s 1QFY21 result was ahead of expectations primarily on the back of sharp jump in Home Insecticides sales. JYL has seen positive sales growth in the month of July as well. Restrictions and strict lockdown in some states are still impacting some operations.

 The overall sentiment has improved and impacted segments are seeing month on month (MoM) improvement. JYL is keeping working capital in check by not extending credit, operating on cash basis & making prepayment to suppliers with longstanding relationships.

 JYL is adding more stockists, strengthening their direct delivery through the retailer’s app and enhancing focus on e-commerce platforms.

 Favourable RM environment, certain operational efficiencies and calibration of ad-spends as per requirement should aid operational performance. We continue to like JYL’s brand portfolio and the overall opportunity in the hygiene categories.

 We expect Earnings Per Share (EPS) to rise by 17.5% in FY21 and by 9% in FY22. The combination of reasonable valuations and JYL’s portfolio promise keeps us constructive. Recommend ADD with a FV of Rs160.

Jyothy Laboratories Ltd: ADD
Dated: 10th August 2020
CMP: Rs.142
Fair Value: Rs.160
Potential Upside: 12.7%
Market Cap: Rs.5200 Cr
Time Frame: 12 months
Note: The above is a brief note on the company, based on the inputs of KIE research report dated 5th August, 2020, which is available on their website at: https://www.kotaksecurities.com/ksweb/ResearchCall/Fundamental.      
Disclaimer: http://bit.ly/2n5AxIE

Looking to invest in Jyothy Laboratories Ltd and other Indian stocks? Open your trading account with Lakshit Financial

Registered Office: Lakshit Financial, 'Lakshit', ASM 7, Ashwin Sector, Mumbai Agra Highway, CIDCO, Nasik 422009, Maharashtra, India. 
Lakshit Financial - AP Regn. No:- BSE: AP0106730124228 - CASH; NSE: AP029177621 - CASH / F&O / CDS.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please refer the Risk Disclosure Document issued by SEBI and go through the Rights and Obligations and Do's and Dont's issued by Stock Exchanges and Depositories before trading on the Stock Exchanges.

OPEN YOUR ACCOUNT NOW !

Fill in your details and we will get in touch with you.

Products and services available only for People of Indian Origin

Note:  Please note that by submitting the above mentioned details, you are authorising Lakshit Financial to call you and send promotional communication even though you may be registered under DNC. Also, all calls with Lakshit Financial representatives may be recorded for internal quality & training purposes

As an NRI , you can purchase shares or convertible debentures of an Indian company through stock exchanges. All it takes is linking your NRO or NRE account to an active Demat account in India on a repatriable or non-repatriable basis, based on your requirements.  
Learn more:  https://www.lakshitfinancial.com/nri-account

Looking to invest in HOME FIRST FINANCE (HOMEFIRST) and other Indian stocks? Open your NRI Demat Acc

Home First (HFFC) reported 24% earnings growth, with 19% net interest income growth in Q2FY25

30 December 2024
Home First Finance (HOMEFIRST) Home First remains consistent on operational and financial parameters. Home First (HFFC) reported 24% earnings growth, with 19% net interest income growth in Q2FY25. Gross stage-3 ratio was flat qoq at 1.7%, stage-2 ratio declined 6 bps qoq to 1.1%. While other asset classes have reported mixed trends residential home loans, as an asset class, continues to stand tall. Home First, with 85% home loan exposure, is well-placed on the above. We expect the company to deliver 25% earnings CAGR for FY25-27E. We remain assertive with a BUY rating and FV of Rs1,360 (no change). Note: The above is a brief note on the company, based on the inputs of KIEresearch report dated 25111Oct, 2024, which is available onour website at: https://www.kotaksecurities.com/ksweb/ResearchCall/Fundamenta1. Disclaimer: http://bit.ly/2n5Ax1E https://www.kotaksecurities.oom/ksweb/research/kotak-research-reports/top-weekly-picks
Looking to invest in SAMHI HOTELS LTD and other Indian stocks? Open your NRI Demat & Trading Account

SAMHI is among India's largest hotel ownership & asset management platforms.

4 December 2023
OPEN
Looking to invest in INFOSYS LTD and other Indian stocks? Open your NRI Demat & Trading Account

Infosys signed 21 large deals in Q2FY24

21 November 2023
OPEN
Looking to invest in Interglobe Aviation and other Indian stocks? Open your NRI Demat & Trading Acco

Pricing woes unlikely to continue much beyond Q2FY24 for lnterGlobe Aviation

9 October 2023
OPEN
Looking to invest in CANARA BANK and other Indian stocks? Open your NRI Demat & Trading Account

Canara Bank reported 75% yoy earnings growth

31 July 2023
OPEN
Macro opportunities are still quite large for even a large bank like HDFC Bank

Macro opportunities are still quite large for even a large bank like HDFC Bank

10 July 2023
OPEN
Looking to invest in CESC and other Indian stocks? Open your NRI Demat & Trading Account with ease

CESC's strong headline grows (28% yoy) primarily on the back of higher unit sales

12 September 2022
OPEN
ICICI Prudentials inexpensive valuation drive Buy rating with fair value of Rs. 650

ICICI Prudential's inexpensive valuation drive Buy rating with fair value of Rs. 650

25 July 2022
OPEN
Looking to invest in Lodha and other Indian stocks? Open your NRI Demat & Trading Account

Lodha clocked Rs9,020 cr (+51% yoy) pre-sales during FY2022

2 May 2022
OPEN
Looking to invest in HDFC Bank and other Indian stocks? Open your NRI Demat & Trading Account

HDFC Bank reported 23% yoy earnings growth.

25 April 2022
OPEN
More posts
Share by:
gtag('config', 'AW-634979631');